Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in unresectable hepatocellular carcinoma
NCT00627042Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2008
- Primary completion
- May 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Started Feb 2008; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00627042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00627042.